Generics 20

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Nilotinib manufacturers

20 products found

Filters

20 products found

nilotinib

Capsules 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #15017
A pharmaceutical manufacturer based in the EU that has been active for 20+ years. The main therapeutic areas include oncology. The company's production lines are GMP-compliant.

Manufacturer usually replies in 5 days

nilotinib

Capsules 150mg, 200mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Available for
Distribution only
Manufacturer #1250

Manufacturer usually replies in 6 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
FDA, EU GMP, ANVISA, Libya, Saudi Arabia, South Korea
Unavailable markets
Saudi Arabia , Vietnam
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 8 days

nilotinib

Capsules, hard liquid 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 9 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q2 2024
Manufacturer #519

Manufacturer usually replies in 6 days

nilotinib

Capsules 200 mg, 400 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Dossier availability date: Q4 2024
Manufacturer #17047
A pharmaceutical manufacturer based in the EU that sells its products in Europe, the Middle East, CIS, LATAM, and Asia. Key production lines are pharmaceuticals, bio and nanopharmaceuticals, medical devices, and nutraceuticals. The main therapeutic area is oncology.

Manufacturer usually replies in 10 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
France , Germany , Gibraltar , Greece , Hungary , Iceland , Ireland , Italy , Isle Of Man , Jersey , Kosovo , Latvia , Liechtenstein , Lithuania , Luxembourg , North Macedonia , Malta , Montenegro , Moldova , Monaco , Netherlands , Norway , Poland , Portugal , Serbia , San Marino , Slovakia , Slovenia , Spain , Svalbard And Jan Mayen , Sweden , Switzerland , Ukraine , United Kingdom , Vatican
Available for
Licensing with supply
Comments
Indication: Antibiotic; Status: Under Development Q1 2024
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Turkey
GMP approvals
EU GMP
Unavailable markets
Bulgaria , Costa Rica , Vietnam , Albania , Bosnia And Herzegovina , Kosovo , Serbia , Slovenia
Registered in
Turkey
Manufacturer #361

It is a global player with more than half a century of experience. It has more than 4 facilities to operate from. They have marketing and promotion in more than 20 countries. It exports to more than 50 countries. The only motto is to improve the quality of human life and to provide access to reliable, high-quality products for human health worldwide. It is focused to create its own cadres in every country it operates.

Manufacturer usually replies in 9 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Manufacturer #1338

Manufacturer usually replies in 7 days

nilotinib

Capsules 150 mg , 200 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Panama , Turkey , Vietnam
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

nilotinib

Capsules 150 mg, 200 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
EU GMP
Manufacturer #12677

Manufacturer usually replies in 4 days

nilotinib

Capsules 150 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Jordan
GMP approvals
Jordan
Manufacturer #20797
A state of art GMP manufacturing site for medicinal products, medical devices, herbal products, and solid cosmetics. The company has an active pipeline of niche pharmaceutical products marketed in the MENA region and Europe under the company’s branding. The company also offers pipeline products with a private label under special agreements.

Manufacturer usually replies in 3 days

nilotinib

Capsules 150 mg, 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18530

Manufacturer usually replies in 4 days

nilotinib

Capsules 50 mg, 150 mg, 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Malaysia
GMP approvals
WHO, PICS, Malaysia
Unavailable markets
Brunei , Malaysia , Singapore
Available for
Licensing with supply, Distribution only, Technology transfer
Comments
Expected registration and CPP from Malaysia in Q1 2025.
Manufacturer #25654

Manufacturer usually replies in 3 days

nilotinib

Capsules 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19670

Manufacturer usually replies in 8 days

nilotinib

Capsules 150 mg, 200 mg

Dossier type
CTD
Dossier status
Outdated
Country of origin
India
GMP approvals
WHO
Manufacturer #31073

Manufacturer usually replies in 6 days

nilotinib

Capsules 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19912

Manufacturer usually replies in 18 days

nilotinib

Capsules 150 mg, 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30830

nilotinib

Capsules 150 mg, 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
China
GMP approvals
China
Manufacturer #30443

nilotinib

Capsules 200 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30013

Manufacturer usually replies in 2 days

Want to view all 20 products? Create your free account today!

What is the drug Nilotinib?

Nilotinib is a selective tyrosine kinase inhibitor. Nilotinib is medication to treat blood cancer and, more precisely, patients with Philadelphia chromosome-positive chronic myelogenous leukemia. The nilotinib drug is usually used when other treatments have failed; it is to overcome Imatinib when patients are resistant to this drug. Nilotinib is a second-generation tyrosine kinase inhibitor. Due to its rare use, Nilotinib is considered an “orphan medicine.”
Nilotinib medication was approved in 2007 by the FDA and in 2009 by the EU EMA. Nilotinib is on the list of the World Health Organization’s essential medicines.

Nilotinib wholesalers and manufacturers:

Novartis manufactures Nilotinib under the name Tasigna. Novartis is also the marketing authorization holder.
Nilotinib suppliers market it in the form of oral capsules. Nilotinib can be found in capsules of 50 mg, 100 mg, and 200 mg.

Nilotinib for sales:

The retail prices of Nilotinib depend on the dosage of the capsule. In the US, for a 50 mg capsule, Nilotinib costs around $ 137 per unit, it equals to $ 16,470 for 120 capsules. For 150 mg and 200 mg, one Nilotinib capsule costs $ 137, and for 28 capsules, it costs $ 3,850.
Nilotinib is mostly available from the European Union, India, and the United States on the Pipelinepharma B2B marketplace. If you are looking for Nilotinib manufacturers, our online platform will help Nilotinib distributors to connect globally with qualified manufacturers that have been verified through quality control procedures. On Pipelinepharma website, you can find a list of many pharmaceutical products, including Nilotinib. Thanks to our very intuitive website, you can easily place an order for Nilotinib and be in relation with Nilotinib manufacturers.

How to use Nilotinib drug?

Depending on the phase the patient is in, the Nilotinib dosage will be adjusted. For a newly diagnosed patient, the usual dose for an adult is 300 mg taken twice a day. For a resistant patient, the prescription for an adult is 400 mg taken twice a day. In both cases, Nilotinib drugs must be taken orally within 12 hours in between the two doses. It is better to take Nilotinib medication on an empty stomach; it means no food 2 hours before taking the drug and 1 hour after taking it.
Nilotinib medication can have some side effects; the most common ones are nausea, rash, headache, and fatigue. Patients should not take Nilotinib if they are allergic if they have low blood levels of potassium or magnesium or a heart rhythm disorder called long QT syndrome.
It must be stored at room temperature, away from heat, moisture, and direct light.